Attached files

file filename
8-K - 8-K - Radius Health, Inc.a14-20168_68k.htm
EX-1.1 - EX-1.1 - Radius Health, Inc.a14-20168_6ex1d1.htm

Exhibit 5.1

 

 

 

John Hancock Tower, 27th Floor

 

200 Clarendon Street

 

Boston, Massachusetts 02116

 

Tel: +1.617.948.6000 Fax: +1.617.948.6001

 

www.lw.com

 

 

 

FIRM / AFFILIATE OFFICES

 

Abu Dhabi

Milan

 

Barcelona

Moscow

 

Beijing

Munich

 

Boston

New Jersey

 

Brussels

New York

 

Chicago

Orange County

 

Doha

Paris

October 2, 2014

Dubai

Riyadh

 

Düsseldorf

Rome

 

Frankfurt

San Diego

 

Hamburg

San Francisco

 

Hong Kong

Shanghai

Radius Health, Inc.

Houston

Silicon Valley

950 Winter Street

London

Singapore

Waltham, Massachusetts 02451

Los Angeles

Tokyo

 

Madrid

Washington, D.C.

 

Re:                             Registration Statement on Form S-3 (No. 333-198513);

2,750,000 shares of Common Stock, par value $0.0001 per share

 

Ladies and Gentlemen:

 

We have acted as special counsel to Radius Health, Inc., a Delaware corporation (the “Company”), in connection with the proposed issuance of up to 2,750,000 shares of common stock of the Company, $0.0001 par value per share (“Common Stock”), including up to 412,500 shares of Common Stock issuable upon exercise of the underwriters’ option to purchase additional shares (the “Shares”).  The Shares are included in a registration statement on Form S-3 under the Securities Act of 1933, as amended (the “Act”), filed with the Securities and Exchange Commission (the “Commission”) on September 2, 2014 (Registration No. 333—198513) (the “Registration Statement”), and are being offered pursuant to a base prospectus dated September 12, 2014 (the “Base Prospectus”), a preliminary prospectus supplement dated October 1, 2014 filed with the Commission pursuant to Rule 424(b) under the Act (together with the Base Prospectus, the “Preliminary Prospectus”) and a prospectus supplement dated October 2, 2014 filed with the Commission pursuant to Rule 424(b) under the Act (together with the Base Prospectus, the “Prospectus”).  The Shares are being sold pursuant to an underwriting agreement dated October 2, 2014 between Jefferies LLC and Cowen and Company, LLC, as the representatives of the several underwriters, and the Company (the “Underwriting Agreement”).  This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement, the Preliminary Prospectus or the Prospectus, other than as expressly stated herein with respect to the issue of the Shares.

 

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter.  With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters

 



 

October 2, 2014

Page 2

 

 

without having independently verified such factual matters.  We are opining herein as to the General Corporation Law of the State of Delaware (the “DGCL”), and we express no opinion with respect to any other laws.

 

Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the Underwriting Agreement, the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable.  In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.

 

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act.  We consent to your filing this opinion as an exhibit to the Company’s Current Report on Form 8-K filed with the Commission on October 2, 2014 and to the reference to our firm in the Prospectus under the heading “Legal Matters.”  In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

 

 

Very truly yours,

 

 

 

/s/ Latham & Watkins LLP